NASDAQ:MYL - Mylan Stock Price, News, & Analysis

Mylan trades on the NASDAQ under the ticker symbol "MYL."

Mylan NV (NASDAQ:MYL) posted its quarterly earnings results on Wednesday, August, 8th. The company reported $1.07 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $1.22 by $0.15. The company had revenue of $2.81 billion for the quarter, compared to analyst estimates of $2.95 billion. Mylan had a return on equity of 18.48% and a net margin of 3.90%. The firm's revenue for the quarter was down 5.2% compared to the same quarter last year. During the same period last year, the firm earned $1.10 EPS. View Mylan's Earnings History.

Mylan is scheduled to release their next quarterly earnings announcement on Monday, November, 5th 2018. View Earnings Estimates for Mylan.

Mylan issued an update on its FY18 earnings guidance on Wednesday, August, 8th. The company provided earnings per share guidance of $4.55-4.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.25. The company issued revenue guidance of $11.25-12.25 billion, compared to the consensus revenue estimate of $12.19 billion.

20 analysts have issued 1-year price targets for Mylan's shares. Their forecasts range from $29.39 to $59.00. On average, they expect Mylan's share price to reach $46.6521 in the next year. This suggests a possible upside of 20.4% from the stock's current price. View Analyst Price Targets for Mylan.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 5 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mylan.

Mylan saw a decline in short interest in July. As of July 31st, there was short interest totalling 9,703,368 shares, a decline of 16.3% from the July 13th total of 11,598,086 shares. Based on an average daily trading volume, of 3,251,151 shares, the days-to-cover ratio is presently 3.0 days. Currently, 2.0% of the shares of the company are sold short. View Mylan's Current Options Chain.

Some companies that are related to Mylan include Bayer (BAYRY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), UCB (UCBJF) and GRIFOLS S A/S (GRFS).

Press coverage about MYL stock has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Mylan earned a coverage optimism score of 0.06 on Accern's scale. They also gave headlines about the company an impact score of 46.22 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Mylan.

Mylan's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.73%), Pzena Investment Management LLC (4.10%), Bank of New York Mellon Corp (1.83%), FMR LLC (1.78%), Menora Mivtachim Holdings LTD. (1.36%) and Janus Henderson Group PLC (1.05%). Company insiders that own Mylan stock include Anthony Mauro, Heather M Bresch, Laboratories Abbott, Paul Campbell, Rajiv Malik and Robert J Coury. View Institutional Ownership Trends for Mylan.

MYL stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Wells Fargo & Company MN, Laurion Capital Management LP, Bank of Montreal Can, Point72 Asset Management L.P., Ivory Investment Management LLC, Los Angeles Capital Management & Equity Research Inc. and Bank of Nova Scotia. Company insiders that have sold Mylan company stock in the last year include Anthony Mauro, Heather M Bresch, Paul Campbell, Rajiv Malik and Robert J Coury. View Insider Buying and Selling for Mylan.

MYL stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Orbimed Advisors LLC, Kornitzer Capital Management Inc. KS, Clal Insurance Enterprises Holdings Ltd, Dimensional Fund Advisors LP, Advisors Asset Management Inc., Great West Life Assurance Co. Can and Bellevue Group AG. View Insider Buying and Selling for Mylan.

Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MYL stock can currently be purchased for approximately $38.75.

Mylan has a market capitalization of $19.67 billion and generates $11.91 billion in revenue each year. The company earns $696 million in net income (profit) each year or $4.56 on an earnings per share basis. Mylan employs 35,000 workers across the globe.

Mylan's mailing address is BUILDING 4 TRIDENT PLACE MOSQUITO WAY, HATFIELD X0, AL10 9UL. The company can be reached via phone at 44-0-17-0785-3000 or via email at [email protected]